Germany · Delayed Price · Currency is EUR N4 Pharma Statistics
Total Valuation
N4 Pharma has a market cap or net worth of EUR 4.80 million. The enterprise value is 2.81 million.
| Market Cap | 4.80M |
| Enterprise Value | 2.81M |
Important Dates
The next estimated earnings date is Monday, March 9, 2026.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 832.28M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +80.86% |
| Shares Change (QoQ) | +45.46% |
| Owned by Insiders (%) | 19.50% |
| Owned by Institutions (%) | 56.72% |
| Float | 517.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 581.82 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 2.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.18 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.55
| Current Ratio | 23.55 |
| Quick Ratio | 23.55 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.18% and return on invested capital (ROIC) is -49.29%.
| Return on Equity (ROE) | -74.18% |
| Return on Assets (ROA) | -47.21% |
| Return on Invested Capital (ROIC) | -49.29% |
| Return on Capital Employed (ROCE) | -67.97% |
| Revenue Per Employee | 2,061 |
| Profits Per Employee | -321,487 |
| Employee Count | 4 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -81,350 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 48.15 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, N4 Pharma had revenue of EUR 8,243 and -1.29 million in losses. Loss per share was -0.00.
| Revenue | 8,243 |
| Gross Profit | 8,243 |
| Operating Income | -1.40M |
| Pretax Income | -1.40M |
| Net Income | -1.29M |
| EBITDA | n/a |
| EBIT | -1.40M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 2.02 million in cash and n/a in debt, with a net cash position of 2.02 million.
| Cash & Cash Equivalents | 2.02M |
| Total Debt | n/a |
| Net Cash | 2.02M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.06M |
| Book Value Per Share | 0.00 |
| Working Capital | 2.06M |
Cash Flow
| Operating Cash Flow | -1.20M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -17,001.07% |
| Pretax Margin | -16,977.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
N4 Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -80.86% |
| Shareholder Yield | -80.86% |
| Earnings Yield | -26.81% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
N4 Pharma has an Altman Z-Score of 9.87 and a Piotroski F-Score of 2.
| Altman Z-Score | 9.87 |
| Piotroski F-Score | 2 |